Similar observations were also reported previously that patients with Melan A-reactive CD4+ T cells producing IL-4 had mean survival time of only 6 months compared to 12 months for patients without IL-4 responses in a phase II clinical trial of recombinant human IL-4 in patients with disseminated malignant melanoma [49]. Here, IL4 is linked to melanoma.